Sigma – in Italy in 1957 in Italy in 1957 and achieved global sales of EUR 665 million in 2007.Sigma – tau SpA invests 16 percent of its annual turnover in R & D. Sigma-tau’s 400 R & D staff are currently running 43 R & D projects. A total of 14 NCEs and 12 known molecular entities in 30 different indications are in various stages of development.
Sigma-tau Group is headquartered in Pomezia , and subsidiaries in France, in R & D. Netherlands, Portugal, Germany, the UK and the U.S., as well as in Spain and Sudan, where the group operates two production sites institutions. It has 2,500 employees and an extensive network of licensees worldwide.Patients should be monitored for a period of twelve months after the injection. Company its Investigational New Drug Application to perform this phase I clinical testing has been granted by the U.S. Food and Drug Administration in January 2008 . ‘This first injection in patient in the direction of toward in clinical development designed state-of – the-art technology on the posterior segment of of the eye open label which order to develop new therapies for retinopathies said Jerome Martinez, Novagali Pharma is Chief Executive Officer. ‘Thanks Eyeject technology, Cortiject is a significant step with the optimized use of corticosteroids for the back of the eye to expect combined ease, slow release and ocular safety.
To the highly developed products include Vekacia , an orphan product the treatment of vernal keratoconjunctivitis, Cyclokat , one product for the treatment of of moderate to severe the dry eye syndrome and Cortiject for treating diabetic retinopathy. Cationorm , being given to the dry eye symptoms commercialized through France since April 2008. Founded in 2000, Novagali Pharma has 50 employees.. About Novagali Pharma isNovagali Pharma is a specialized in ophthalmology drug companies at Genopole biocluster in Evry , develops and markets innovative product. Founded in 2000oprietary technology platforms Novasorb and Eyeject , the company has developed a broad range of 7 technically innovative solutions for ocular conditions well as orphan diseases.